Randomized, Multicenter, Double-blind, Phase 3 Trial of Tavocept Versus Placebo in Patients With Newly Diagnosed or Relapsed Advanced Primary Adenocarcinoma of the Lung Treated With Docetaxel or Paclitaxel Plus Cisplatin
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Overall Survival
throughout study
No
United States: Food and Drug Administration
DMS32212R
NCT00966914
April 2010
June 2014
Name | Location |
---|---|
Birmingham, Alabama 35294 | |
Columbia, Missouri 65203 | |
Philadelphia, Pennsylvania 19104 | |
Nashville, Tennessee 37203-1632 |